- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Spectrum launches patient-friendly campaign to support Zevalin
Spectrum Pharmaceuticals is launching a new patient campaign surrounding the company's lead oncology product Zevalin for the treatment of follicular lymphoma.
The campaign will debut a quartet of multimedia testimonials/patient stories from real patients with follicular lymphoma who have been treated with the Zevalin regimen. Each person will offer his or her perspectives on themes relavent to the cancer spectrum: diagnosis, treatment options, life before cancer, life after cancer, and on having received Zevalin.
The website, Zevalin.com, has been revamped to serve as the go-to educational resource for patients, caregivers, and healthcare professionals who want to learn more about NHL and Zevalin and they want a trusted, reliable site for that information.
“The stories of these patients on Zevalin.com are very moving and reinforce the centrality of patients in the mission of our company,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals. “Patients today are more empowered through education to take an active role in learning about their treatment options. These four patients and their doctors chose Zevalin. We hope their journeys will inspire and encourage other follicular lymphoma patients to take an active role in educating themselves.
"Follicular lymphoma patients deserve to understand all of their options, including how one therapeutic dose of Zevalin could fit into their treatment plans.”